Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of Docetaxel, Prednisone and Pazopanib in Men With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and Poor-Risk Factors

Next Previous
Trial Profile

Phase I Study of Docetaxel, Prednisone and Pazopanib in Men With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and Poor-Risk Factors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pazopanib (Primary) ; Docetaxel; Pegfilgrastim; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 03 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 03 Feb 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 01 Apr 2014 The study phase was changed from I/II to phase I. Planned patient number was changed from 122 to 36 due to change in the treatment protocol according to the ClinicalTrials.gov record. Endpoints were modified according to ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top